REMOZEN 100 10

About

This medication contains Remogliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, designed for the management of type 2 diabetes mellitus. Remogliflozin works by targeting the SGLT2 proteins in the kidneys, which are responsible for reabsorbing glucose back into the bloodstream. By inhibiting these proteins, Remogliflozin promotes the excretion of excess glucose through the urine, thereby lowering blood glucose levels. This mechanism of action is independent of insulin, making it effective even in patients with impaired insulin secretion. In addition to its glucose-lowering effects, SGLT2 inhibitors like Remogliflozin have been associated with other benefits, including modest weight reduction, blood pressure lowering, and potential cardiovascular and renal protective effects. It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Uses

• Management of type 2 diabetes mellitus in adults.
• Improvement of glycemic control as an adjunct to diet and exercise.
• Reduction of elevated fasting and postprandial blood glucose levels.
• Lowering of HbA1c levels to achieve target glycemic goals.

Directions For Use

Take orally, usually once daily, with or without food as directed by your physician. Swallow the tablet whole with water.

Benefits

• Significant reduction in blood glucose levels.
• Improved long-term glycemic control (HbA1c).
• Potential for modest weight reduction.
• May offer cardiovascular protective effects.
• May provide renal protective benefits.
• Insulin-independent glucose lowering.

Side Effects

• Genital mycotic infections
• Urinary tract infections (UTIs)
• Increased urination (polyuria)
• Thirst/dehydration
• Nausea
• Constipation
• Back pain
• Dizziness
• Fatigue
• Hypoglycemia (especially with other antidiabetic agents)
• Rarely, diabetic ketoacidosis

Safety Measures

• Alcohol - Limit alcohol intake as it can affect blood sugar levels and may increase the risk of dehydration associated with SGLT2 inhibitors.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor, as the risks and benefits need to be carefully weighed.
• Breastfeeding - Not recommended during breastfeeding due to potential excretion into breast milk and unknown effects on the infant. Consult your doctor.
• Liver - Use with caution in patients with liver impairment. Limited data exist, and close monitoring may be required.
• Kidney - Dose adjustment may be required based on renal function. Contraindicated in severe renal impairment (eGFR below certain thresholds) for SGLT2 inhibitors.
• Lung - Generally safe for use in patients with lung conditions. However, always consult your doctor if you have severe or unstable respiratory issues.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.